{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:32:55Z","timestamp":1774657975251,"version":"3.50.1"},"reference-count":35,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/lmej4113","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T06:12:04Z","timestamp":1767075124000},"page":"5213-5230","source":"Crossref","is-referenced-by-count":1,"title":["A predictive model based on BRCA1\/2, POLE, TP53, and MSH6 mutations for immunotherapy response in advanced endometrial cancer"],"prefix":"10.62347","volume":"15","author":[{"given":"Yancai","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cpt.2023.10.003","article-title":"Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer","volume":"2","author":"Shukla","year":"2024","unstructured":"Shukla S, Patel H, Chen S, Sun R, Wei L and Chen ZS. Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer. Cancer Pathog Ther 2024; 2: 135-141.","journal-title":"Cancer Pathog Ther"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.20517\/cdr.2023.120","article-title":"The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer","volume":"7","author":"Martinez-Cannon","year":"2024","unstructured":"Martinez-Cannon BA and Colombo I. The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer. Cancer Drug Resist 2024; 7: 23.","journal-title":"Cancer Drug Resist"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG and Fleming GF. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer 2022; 10: e004233.","DOI":"10.1136\/jitc-2021-004233"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Patel SP, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD and Carneiro BA. Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. J Immunother Cancer 2024; 12: e007340.","DOI":"10.1136\/jitc-2023-007340"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, Osokin N, Kozlov I, Frenkel F, Gancharova O, Almog N, Tsiper M, Ataullakhanov R and Fowler N. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 2021; 39: 845-865, e847.","DOI":"10.1016\/j.ccell.2021.04.014"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3390\/cancers15072042","article-title":"Immune environment and immunotherapy in endometrial carcinoma and cervical tumors","volume":"15","author":"Lain&#xE9","year":"2023","unstructured":"Lainé A, Gonzalez-Lopez AM, Hasan U, Ohkuma R and Ray-Coquard I. Immune environment and immunotherapy in endometrial carcinoma and cervical tumors. Cancers (Basel) 2023; 15: 2042.","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Wei W, Ban X, Yang F, Li J, Cheng X, Zhang R, Huang X, Huang Y, Li Q, Qiu Y, Zheng M, Zhu X and Li J. Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer. J Immunother Cancer 2022; 10: e004338.","DOI":"10.1136\/jitc-2021-004338"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/biom12081031","article-title":"Dostarlimab: a review","volume":"12","author":"Costa","year":"2022","unstructured":"Costa B and Vale N. Dostarlimab: a review. Biomolecules 2022; 12: 1031.","journal-title":"Biomolecules"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.3390\/jcm12175540","article-title":"The revolution of immunotherapy in gynecological cancers: the lazarus effect in endometrial cancer","volume":"12","author":"Ducceschi","year":"2023","unstructured":"Ducceschi M, Polignano M, Bini M, Lopez S, Conca E, Tamborini E, Perrone F, Carlo Stella G, Petrella MC, Carciotto R, Artioli G, Maffeis V, Sartor L, Raspagliesi F and Mantiero M. The revolution of immunotherapy in gynecological cancers: the lazarus effect in endometrial cancer. J Clin Med 2023; 12: 5540.","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/14737140.2022.2044311","article-title":"Immune checkpoint inhibitors for recurrent endometrial cancer","volume":"22","author":"Mutlu","year":"2022","unstructured":"Mutlu L, Harold J, Tymon-Rosario J and Santin AD. Immune checkpoint inhibitors for recurrent endometrial cancer. Expert Rev Anticancer Ther 2022; 22: 249-258.","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O’Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C, III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J and Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer 2022; 10: e003777.","DOI":"10.1136\/jitc-2021-003777"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ygyno.2018.05.015","article-title":"Endometrial cancer: molecular markers and management of advanced stage disease","volume":"150","author":"Arend","year":"2018","unstructured":"Arend RC, Jones BA, Martinez A and Goodfellow P. Endometrial cancer: molecular markers and management of advanced stage disease. Gynecol Oncol 2018; 150: 569-580.","journal-title":"Gynecol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1007\/s00330-023-10435-3","article-title":"From RECIST to PERCIST: navigating the landscape of tumor response assessment","volume":"34","author":"Leong","year":"2024","unstructured":"Leong WL. From RECIST to PERCIST: navigating the landscape of tumor response assessment. Eur Radiol 2024; 34: 3656-3658.","journal-title":"Eur Radiol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Disis ML, Adams SF, Bajpai J, Butler MO, Curiel T, Dodt SA, Doherty L, Emens LA, Friedman CF, Gatti-Mays M, Geller MA, Jazaeri A, John VS, Kurnit KC, Liao JB, Mahdi H, Mills A, Zsiros E and Odunsi K. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. J Immunother Cancer 2023; 11: e006624.","DOI":"10.1136\/jitc-2022-006624"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Li Y, Wang X, Hou X and Ma X. Could inhibiting the DNA damage repair checkpoint rescue immune-checkpoint-inhibitor-resistant endometrial cancer? J Clin Med 2023; 12: 3014.","DOI":"10.3390\/jcm12083014"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"844801","DOI":"10.3389\/fonc.2022.844801","article-title":"How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review","volume":"12","author":"Maiorano","year":"2022","unstructured":"Maiorano BA, Maiorano MFP, Cormio G, Maglione A, Lorusso D and Maiello E. How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review. Front Oncol 2022; 12: 844801.","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.32074\/1591-951X-791","article-title":"In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay","volume":"114","author":"Fumagalli","year":"2022","unstructured":"Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, Vacirca D, Colombo N and Barberis M. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Pathologica 2022; 114: 288-294.","journal-title":"Pathologica"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"109304","DOI":"10.1016\/j.intimp.2022.109304","article-title":"Targeting STING for cancer immunotherapy: from mechanisms to translation","volume":"113","author":"Huang","year":"2022","unstructured":"Huang R, Ning Q, Zhao J, Zhao X, Zeng L, Yi Y and Tang S. Targeting STING for cancer immunotherapy: from mechanisms to translation. Int Immunopharmacol 2022; 113: 109304.","journal-title":"Int Immunopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"17588359221099347","DOI":"10.1177\/17588359221099347","article-title":"Microsatellite instability and chemosensitivity in solid tumours","volume":"14","author":"Cherri","year":"2022","unstructured":"Cherri S, Oneda E, Noventa S, Melocchi L and Zaniboni A. Microsatellite instability and chemosensitivity in solid tumours. Ther Adv Med Oncol 2022; 14: 17588359221099347.","journal-title":"Ther Adv Med Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12672-024-01315-3","article-title":"Pyroptosis-associated genes and tumor immune response in endometrial cancer","volume":"15","author":"Gong","year":"2024","unstructured":"Gong X, Wang Z, You J, Gao J, Chen K, Chu J, Sui X, Dang J and Liu X. Pyroptosis-associated genes and tumor immune response in endometrial cancer. Discov Oncol 2024; 15: 433.","journal-title":"Discov Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.3390\/cancers15184632","article-title":"Immune checkpoint inhibitors targeting the PD-1\/PD-L1 pathway in advanced, recurrent endometrial cancer: a scoping review with SWOT analysis","volume":"15","author":"Johnson","year":"2023","unstructured":"Johnson RL, Ganesan S, Thangavelu A, Theophilou G, de Jong D, Hutson R, Nugent D, Broadhead T, Laios A, Cummings M and Orsi NM. Immune checkpoint inhibitors targeting the PD-1\/PD-L1 pathway in advanced, recurrent endometrial cancer: a scoping review with SWOT analysis. Cancers (Basel) 2023; 15: 4632.","journal-title":"Cancers (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Yu J, Ling S, Hong J, Zhang L, Zhou W, Yin L, Xu S, Que Q, Wu Y, Zhan Q, Bao J, Xu N, Liu Y, Chen K, Wei X, Liu Z, Feng T, Zhou L, Xie H, Wang S, Liu J, Zheng S and Xu X. TP53\/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma. J Immunother Cancer 2023; 11: e007479.","DOI":"10.1136\/jitc-2023-007479"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3390\/cancers16051028","article-title":"Recent advances in endometrial cancer prevention, early diagnosis and treatment","volume":"16","author":"Baker-Rand","year":"2024","unstructured":"Baker-Rand H and Kitson SJ. Recent advances in endometrial cancer prevention, early diagnosis and treatment. Cancers (Basel) 2024; 16: 1028.","journal-title":"Cancers (Basel)"},{"key":"ref23","unstructured":"Mirza MR, Chase DM, Slomovitz BM, Christensen RD, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL and Powell MA. A plain language summary of “dostarlimab for primary advanced or recurrent endometrial cancer”. Future Oncol 2025; 21: 151-168."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/14737140.2024.2367472","article-title":"Immunotherapy in MMR-d\/MSI-H recurrent\/metastatic endometrial cancer","volume":"24","author":"Pacholczak-Madej R","year":"2024","unstructured":"Pacholczak-Madej R, Bartoletti M, Musacchio L, Püsküllüoglu M, Blecharz P and Lorusso D. Immunotherapy in MMR-d\/MSI-H recurrent\/metastatic endometrial cancer. Expert Rev Anticancer Ther 2024; 24: 717-729.","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Zhou C, Xiang P, Xu X, Yue C and Gao K. The inflammatory response-related robust machine learning signature in endometrial cancer: based on multi-cohort studies. J Gene Med 2024; 26: e3603.","DOI":"10.1002\/jgm.3603"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"7904","DOI":"10.3390\/curroncol30090574","article-title":"An overview of endometrial cancer with novel therapeutic strategies","volume":"30","author":"TM","year":"2023","unstructured":"Kuhn TM, Dhanani S and Ahmad S. An overview of endometrial cancer with novel therapeutic strategies. Curr Oncol 2023; 30: 7904-7919.","journal-title":"Curr Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ijgc-2022-003675","article-title":"Immunotherapy in endometrial cancer","volume":"33","author":"Mahdi","year":"2023","unstructured":"Mahdi H, Chelariu-Raicu A and Slomovitz BM. Immunotherapy in endometrial cancer. Int J Gynecol Cancer 2023; 33: 351-357.","journal-title":"Int J Gynecol Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/cncr.35030","article-title":"Characterization of mismatch-repair\/microsatellite instability-discordant endometrial cancers","volume":"130","author":"Riedinger","year":"2024","unstructured":"Riedinger CJ, Esnakula A, Haight PJ, Suarez AA, Chen W, Gillespie J, Villacres A, Chassen A, Cohn DE, Goodfellow PJ and Cosgrove CM. Characterization of mismatch-repair\/microsatellite instability-discordant endometrial cancers. Cancer 2024; 130: 385-399.","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1101\/gad.349431.122","article-title":"DNA repair defects in cancer and therapeutic opportunities","volume":"36","author":"JL","year":"2022","unstructured":"Hopkins JL, Lan L and Zou L. DNA repair defects in cancer and therapeutic opportunities. Genes Dev 2022; 36: 278-293.","journal-title":"Genes Dev"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","unstructured":"Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P and Dumbrava EE. Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer. J Clin Oncol 2024; 42: 3421-3429.","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z, Cherry C, Balan A, Pereira G, Curry A, Niknafs N, Zhang J, Smith KN, Sivapalan L, Chaft JE, Reuss JE, Marrone K, Murray JC, Li QK, Lam V, Levy BP, Hann C, Velculescu VE, Brahmer JR, Forde PM, Seiwert T and Anagnostou V. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer 2022; 10: e004688.","DOI":"10.1136\/jitc-2022-004688"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, Wei J, Peng Z, Wang X, Zhou J, Qi C, Liu D, Li J, Lu M, Lu Z, Cao Y, Yuan J, Zhang R, Fang J, Zhang X and Shen L. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine 2024; 68: 102415.","journal-title":"EClinicalMedicine"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00018-022-04431-x","article-title":"Generation, secretion and degradation of cancer immunotherapy target PD-L1","volume":"79","author":"Shen","year":"2022","unstructured":"Shen DD, Bi YP, Pang JR, Zhao LJ, Zhao LF, Gao Y, Wang B, Liu HM, Liu Y, Wang N, Zheng YC and Liu HM. Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cell Mol Life Sci 2022; 79: 413.","journal-title":"Cell Mol Life Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.bulcan.2023.06.009","article-title":"Real-world dostarlimab use in advanced\/recurrent endometrial cancer in France","volume":"110","author":"Rodrigues","year":"2023","unstructured":"Rodrigues M, Eberst L, Follana P, Gauthier L, Jacquemin V, Tessier C, El Mouaddin N, Boudier P, Fiteni F, Angeli E, Roche S, Delanoy N, Sabatier R, Flippot R and de la Motte Rouge T. Real-world dostarlimab use in advanced\/recurrent endometrial cancer in France. Bull Cancer 2023; 110: 1041-1050.","journal-title":"Bull Cancer"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:05:37Z","timestamp":1768975537000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/12\/ajcr0167380.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/lmej4113","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}